Alfredo Puing (@alfredopuing) header
Alfredo Puing (@alfredopuing) profile picture

Alfredo Puing

@alfredopuing

🇪🇨Ecuadorian | ID doc @YaleMed

 New Haven, CT
medicine.yale.edu/profile/alfredo-puing/
Joined April 2010
  • Tweets405
  • Following484
  • Followers491
Happy Sunday everyone! We're the official account for The Journal of Infectious Diseases – an official journal of @IDSAInfo. Follow us for updates and to comment on the latest articles from JID, the premier global journal for original research on infectious diseases.
2
38
249
Hi everyone! 👋 We're the official account for Clinical Infectious Diseases. An official journal of @IDSAinfo, CID is one of the world's leading journals on ID. Follow us to stay up to date and comment on high-quality articles on clinical ID, public health, microbiology & more.
10
124
12
767
Hello there! We're the official account for Open Forum Infectious Diseases – an official journal of @IDSAInfo. OFID publishes clinical, translational and basic research in a fully open access, online journal. Follow us to stay up to date and comment on all our latest content.
2
55
4
305
New job opportunity @cityofhope - Assistant Clinical Professor in Infectious Diseases w/ a focus on HCT and cancer pts. Great team of experts that you would be joining. Plus ☀️ California... See here for more information bit.ly/3B9iJ3i
Image from TransplantID Journal (@TheTxIDjournal)
3
7
Happy to share our research letter on TMP-SMX avoidance and nocardiosis - 💊TMP-SMX allergy evaluation/rechallenge on pts receiving 2nd line PJP ppx may allow its tolerance and could prevent other OIs - Great work @AnneLiuMD @ArunaSubraman12 !! wwwnc.cdc.gov/eid/article/27…
Image from Alfredo Puing (@alfredopuing)
1
4
2
22
Alfredo Puing retweeted
U.S. FDA (@FDA) profile picture
U.S. FDA
@FDA13 Aug 2021
Today, FDA amended the emergency use authorizations (EUAs) for both the Pfizer-BioNTech COVID-19 Vaccine and the Moderna COVID-19 Vaccine to allow for the use of an additional dose in certain immunocompromised individuals. go.usa.gov/xFVdR
Image from U.S. FDA (@FDA)
175
918
323
1,558
FDA authorizes REGEN-COV (casirivimab-imdevimab) for post-exposure prophylaxis in adults and pediatric individuals who are at high risk for progression to severe COVID-19, including hospitalization or death. fda.gov/drugs/drug-safety-an…
FDA authorizes REGEN-COV mAb for prevention for COVID-19

FDA authorizes REGEN-COV mAb for prevention for COVID-19

Prophylaxis with REGEN-COV is not a substitute for vaccination against COVID-19

fda.gov
3
6
Una poesía con versos aclamados por un pequeño pueblo. Este oro es para quien realmente ha creído en mí. También para mis hijos, esposa y mis padres. Los amo! Sepan seguro que los días más grandes se escriben con la misma tinta de olimpo. Gracias Ecuador 🇪🇨
Image from Richard Carapaz M (@RichardCarapazM)
5,718
21,241
3,489
123,172
Alfredo Puing retweeted
Eric Topol (@EricTopol) profile picture
Eric Topol
@EricTopol1 Jul 2021
In California, the Delta variant is 30% of cases, and vaccinations are fairly high (>61% population 1-dose or more), cases have started to creep up again, 17% in past 2 weeks and that's with 62% less testing (<-complacency)
Image from Eric Topol (@EricTopol)
39
201
31
477
Alfredo Puing retweeted
ID Journal Club (@IDJClub) profile picture
ID Journal Club@IDJClub23 Apr 2021
Next #IDJClub: May 3 (9pm EDT) In honor of our late colleague and friend Francisco Marty, a giant in the field of infections of immunocompromised hosts, we’ll discuss posaconazole vs voriconazole as primary therapy for invasive #aspergillosis thelancet.com/journals/lance…
Image from ID Journal Club (@IDJClub)
4
57
10
197
Dont forget to cast your vote in the 2021 COP election @AST_IDCOP I'm running for early career member-at-large and would love your support! #TxID #vote
1
2
1
6
Ivermectin had no role in management of mild COVID-19. @alfredopuing @MarianaLanata @camillewebb @MauricioLaRosa1 Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 ja.ma/3bh0TAg via @JAMA_current part of @JAMANetwork
Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19

Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19

This randomized trial compares the effects of ivermectin vs placebo on time to symptom resolution within 21 days among patients with mild COVID-19.

jamanetwork.com
8
1
14
If someone tests positive for COVID but is admitted for reasons other than COVID but has risk factors for progressing to severe disease. What treatment would you give? @AnnieC_ID_MD @Darcy_ID_doc @BalcombeShannon @OncIDPharmd @ErinMcCreary @IDRoadrunner @DHpharmd
9%Remdesivir + mAb
18%Remdesivir alone
32%mAb alone
41%No treatment
357 votes • Final results
9
5
4
🏆 B.S.C.
2
Updated guidelines on management of #COVID19 - WHO: doi.org/10.1136/bmj.m3379 - NIH: covid19treatmentguidelines.n… - IDSA: idsociety.org/COVID19guideli…
Image from Alfredo Puing (@alfredopuing)
NEJM Clinician (@NEJMClinician) profile pictureNEJM Clinician@NEJMClinician5 Dec 2020
Updated treatment guidelines for #COVID19 @WHO @IDSAInfo @NIH jwat.ch/36G3AsE
Image from NEJM Clinician (@NEJMClinician)
1
Many more to come... #COVID19 #vaccines
Image from Alfredo Puing (@alfredopuing)
4
How it started. How is it going.
Image from Alfredo Puing (@alfredopuing)
Image from Alfredo Puing (@alfredopuing)
8
4
313
#Remdesivir 5 vs 10 day treatment for severe #Covid_19 results- Congrats to our hardworking clinical team! @StanfordDeptMed @StanfordASP
Francisco Marty, MD (@FranciscoMarty_) profile pictureFrancisco Marty, MD@FranciscoMarty_27 May 2020
#Remdesivir 5 vs. 10 day treatment trial for #severe #COVID19 is out! - 5 days enough for most patients (shorter is good) - Outcome strongly influenced by severity of disease within stratum (earlier is better) - Outcomes comparable to #ACTT1 overall link:nejm.org/doi/full/10.1056/NE…
Image from Francisco Marty, MD (@FranciscoMarty_)
Image from Francisco Marty, MD (@FranciscoMarty_)
Image from Francisco Marty, MD (@FranciscoMarty_)
12
27
Alfredo Puing retweeted
The Lancet (@TheLancet) profile picture
The Lancet
@TheLancet29 Apr 2020
NEW Research—First randomised trial of #remdesivir for hospitalised patients who are critically ill with #COVID19 suggests antiviral drug is not associated with significant clinical benefits vs placebo: study of 237 adults from 10 hospitals in Wuhan (1/5) hubs.ly/H0p-BMJ0
Image from The Lancet (@TheLancet)
75
1,223
417
1,496
THREAD: Lots of alarm over the 🚨88% Mortality🚨among #Covid19 patients on ventilators. The paper *should* say "Among pts on vents, mortality will range from 25-97%". This @JAMA_current study is a great for a JournalClub on "Beware Your Denominator"👇(1/7) jamanetwork.com/journals/jam…
Clinical Characteristics, Comorbidities, and Outcomes Among Patients With COVID-19 Hospitalized in...

Clinical Characteristics, Comorbidities, and Outcomes Among Patients With COVID-19 Hospitalized in...

This case series describes clinical characteristics, health services use, and outcomes of patients with confirmed coronavirus disease 2019 (COVID-19) cared for at 12 hospitals of a single health...

jamanetwork.com
This quoted post is unavailable.
Try viewing anyway · View on X
17
216
104
435
Load more